Bertolo Riccardo, Fiori Cristian, Amparore Daniele, Porpiglia Francesco
Division of Urology, Department of Oncology, School of Medicine, University of Turin-San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Turin, Orbassano, Italy.
Curr Urol Rep. 2018 Apr 26;19(6):44. doi: 10.1007/s11934-018-0793-0.
The purpose of the present systematic review is to offer a narrative synthesis of the available literature regarding the role of the temporary implantable nitinol device (TIND) (Medi-Tate®; Medi-Tate Ltd., Or Akiva, Israel) for the treatment of benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms (LUTS), specifically focusing on the follow-up data.
Current available evidences are limited in this topic. Sample size of patients available for analysis is small. Moreover, the duration of follow-up period is intermediate and longer follow-up is required. At the available 3 years follow-up, the TIND implantation is safe, effective, and well tolerated. The extended follow-up of the first and only available cohort of patients who underwent TIND for LUTS related to BPH corroborated previous literature findings. Further studies are required in order to assess the durability of TIND outcomes over a longer follow-up, to better define the indications of this approach, and to demonstrate the advantages of second-generation device over the first.
本系统综述的目的是对现有文献进行叙述性综合，内容涉及临时植入式镍钛诺装置（TIND）（Medi-Tate®；Medi-Tate Ltd.，以色列奥阿基瓦）在治疗良性前列腺增生（BPH）相关下尿路症状（LUTS）中的作用，特别关注随访数据。
该主题目前可用的证据有限。可供分析的患者样本量较小。此外，随访期为中期，需要更长时间的随访。在现有的3年随访中，TIND植入是安全、有效的，且耐受性良好。对首批也是唯一一批因BPH相关LUTS接受TIND治疗的患者进行的延长随访证实了先前文献的研究结果。需要进一步开展研究，以评估TIND在更长随访期内疗效的持久性，更好地明确这种治疗方法的适应症，并证明第二代装置相对于第一代的优势。
